Inhibrx Biosciences is running a two-program sprint on $219.5 million in cash, a number that includes a freshly drawn $100 million tranche from Oxford Finance, and the next 90 days will determine whether its lead asset, ozekibart, enters commercialization as a genuine revenue engine or as a bridge to something larger. The financial picture is straightforward: a $36.7 million net loss in Q2 2026, up from $28.7 million a year earlier, driven largely by BLA-prep manufacturing costs and pre-launch market access spending. What makes the quarter worth watching is not the burn rate but the convergence of regulatory, clinical, and financing milestones arriving in rapid succession.
The FDA accepted Inhibrx’s biologics license application for ozekibart in conventional chondrosarcoma earlier this year and assigned a PDUFA goal date of April 14, 2027. Chondrosarcoma is a disease long managed without an approved drug specifically targeting the indication, which explains why G&A jumped from $6.4 million to $8.3 million quarter-over-quarter: Inhibrx is building a commercial infrastructure in real time, before approval, a calculated risk that small oncology companies rarely survive if the regulatory decision breaks the wrong way. The Q4 meeting with FDA to discuss a first-line registrational path in colorectal cancer and a potential accelerated approval route in fourth-line CRC is equally important. Two new CRC cohorts launched in Q2, one pairing ozekibart with FOLFIRI and bevacizumab in second-line, another with Lonsurf plus bevacizumab in third and fourth line. Interim data from those cohorts are expected in Q1 2027, timed to inform exactly what Inhibrx asks the agency for in that meeting.
The second program, INBRX-106, adds a near-term binary to the calendar. Earlier interim data from the randomized Phase 2 trial in PD-L1-positive HNSCC showed a confirmed objective response rate numerically higher than pembrolizumab monotherapy, enough to justify pressing forward. Progression-free survival data from that trial in head and neck squamous cell carcinoma, the endpoint that actually moves regulatory conversations with pembrolizumab well established in this setting, is due in Q3 2026. PFS, not response rate, is what separates a signal from a filing-enabling result, and the market knows it.
The single number to track from here is not the Oxford facility ceiling of $325 million or the PDUFA date: it is the PFS hazard ratio in HNSCC expected this quarter. A credible result reshapes Inhibrx’s negotiating position on every front, from partnership discussions to the scope of what it can reasonably request from the FDA for ozekibart in CRC. A disappointing one leaves a company burning roughly $35 million per quarter with one unpartnered program and a commercial launch to fund.
Source link: https://www.prnewswire.com/news-releases/inhibrx-reports-second-quarter-2026-financial-results-302851356.html
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
